• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Gene that Could Identify Tamoxifen-Resistant Breast Cancer Discovered

Article

The study, published in PNAS, identified a gene whose expression could be used as a prognostic indicator and could direct treatment in breast cancer patients.

Johns Hopkins Kimmel Cancer Center identified a gene, MACROD2,

A study conducted by scientists at the which they found is amplified in a subset of breast cancer patients. Deletion and overexpression studies with the gene, in vitro and in a mouse model, found that MACROD2 promotes resistance to tamoxifen and encourages estrogen receptor-independent growth in a mouse xenograft model.

When they examined 2 well-known databases of breast cancer patients' genetic information, The Cancer Genome Atlas and the Molecular Taxonomy of Breast Cancer International Consortium study, it was discovered that patients who had MACROD2 overexpressed in primary breast cancers at the original breast cancer site had significantly worse survival rates than those who did not.

This could mean that patients overexpressing this gene in the primary tumor, early in the disease, could receive aggressive treatment.

The study was published online in PNAS: http://bit.ly/1rcTJBY

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.